Neurotech International (ASX:NTI)
Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism
Jul 10, 2018
Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Related Neurotech International (ASX:NTI) articles
Revolutionary MedTech Device: a New Frontier in Autism Treatment
Jun 26, 2018
Today’s company has created the first and only regulated medical device for the management of autism in a home setting.
ASX Junior’s Under-Drilled Cuban Oil Asset Puts it in Multi-Billion Barrel Company
Nov 15, 2018
Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
Nov 13, 2018